Testagen (20mg)

Testagen (20mg): Bioregulatory Peptide — the 10-Amino-Acid Peptide with the Sequence Lys-Glu-Asp-Ala-Glu-Trp-Leu-Pro-Asp-Arg (also known as Testolactone Peptide or Testogen), a Khavinson Bioregulator Studied for Testicular Function, Male Reproductive Health, Hormonal Balance, and Age-Related Decline

Testagen is a synthetic 10-amino-acid bioregulatory peptide with the sequence Lys-Glu-Asp-Ala-Glu-Trp-Leu-Pro-Asp-Arg (molecular weight approximately 1246 Da). It belongs to the class of Khavinson bioregulatory peptides — a group of short peptides (2-12 amino acids) developed by Professor Vladimir Khavinson and his team at the St. Petersburg Institute of Bioregulation and Gerontology over several decades of research. These bioregulatory peptides are derived from or modeled after naturally occurring peptide fractions isolated from various organs and tissues, and are believed to act as epigenetic regulators — binding to specific regions of DNA (particularly promoter regions of genes associated with the organ from which the peptide was derived) and modulating gene expression to restore and maintain normal cellular function. Testagen is specifically associated with testicular function and male reproductive health — it is modeled after peptide fractions isolated from testicular tissue, and is believed to target genes involved in testosterone production, spermatogenesis (sperm production), Leydig cell function, Sertoli cell function, and overall testicular homeostasis. In Khavinson's peptide bioregulation theory, each organ/tissue has a corresponding "peptide bioregulator" that helps maintain that organ's function as we age — Testagen is the testicular bioregulator, analogous to how other Khavinson peptides target specific organs (e.g., Epitalon for pineal/epiphysis, Thymalin for thymus, Cartalax for cartilage, Chonluten for bronchopulmonary system, Vesugen for blood vessels, Vilon for immune system, Pinealon for brain, Prostamax for prostate, etc.). Testagen has been studied in preclinical and early clinical research for: (1) Testosterone production — Testagen may support Leydig cell function (the cells in the testes that produce testosterone), potentially helping maintain or restore healthy testosterone levels, particularly in age-related decline (andropause/late-onset hypogonadism); (2) Spermatogenesis — Testagen may support Sertoli cell function (the cells that nurture developing sperm cells) and overall sperm production, potentially improving sperm count, motility, and morphology in cases of male infertility or age-related decline; (3) Male reproductive health — overall support of testicular function, reproductive hormone balance, and male fertility; (4) Age-related decline — as a bioregulatory peptide, Testagen is studied for its potential to slow or reverse age-related decline in testicular function, which naturally declines with age (testosterone levels decrease ~1-2% per year after age 30, sperm quality also declines); (5) Hormonal balance — Testagen may help regulate the hypothalamic-pituitary-gonadal (HPG) axis, supporting healthy LH (luteinizing hormone) and FSH (follicle-stimulating hormone) signaling to the testes; (6) Anti-aging/wellness — as part of a broader peptide bioregulation protocol, Testagen may contribute to overall wellness and healthy aging by maintaining testicular function; (7) Recovery from testicular stress — Testagen may help support recovery of testicular function after stressors such as illness, chemotherapy, radiation, or other insults that can temporarily suppress testicular function. Testagen is typically administered by subcutaneous (SC) or intramuscular (IM) injection, though some protocols use intranasal administration. The 20mg vial format provides a convenient quantity for research use. As a bioregulatory peptide, Testagen is generally considered to have a very favorable safety profile — Khavinson peptides are typically well-tolerated with minimal side effects, as they are short peptides that are naturally occurring or modeled after natural peptide fractions, and they act as epigenetic regulators rather than potent pharmacological agents. Common side effects, if any, are typically mild and transient: injection site reactions (mild pain, redness), occasional headache, and (rarely) mild nausea or dizziness. Importantly, Testagen is NOT a direct testosterone replacement — it does NOT contain testosterone, and it does NOT directly replace hormones. Instead, it is believed to support the body's OWN testicular function by regulating gene expression in testicular cells. This means Testagen may have a more physiological, gentle effect compared to exogenous testosterone replacement therapy (TRT), and may be less likely to cause the side effects associated with TRT (such as suppression of endogenous testosterone, testicular atrophy, infertility, etc.). However, the research on Testagen is more limited than for some other peptides, and much of the data comes from Russian/Eastern European research (Khavinson's work) that may be less well-known in Western medical literature. As of 2026, Testagen is NOT FDA-approved for any indication in the US — it is a research-grade/investigational compound used in peptide bioregulation research. The research-grade Testagen supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

Detailed Analysis: Testagen as a Khavinson Bioregulatory Peptide — Mechanisms, Research, and Practical Considerations

1. The Khavinson Peptide Bioregulation Theory: Professor Vladimir Khavinson (1947-2024) and his team at the St. Petersburg Institute of Bioregulation and Gerontology developed the theory of peptide bioregulation over more than 40 years of research. The core premise is that short peptides (2-12 amino acids) act as epigenetic regulators — they can bind to specific regions of DNA (particularly the promoter regions of genes associated with the organ/tissue from which the peptide was derived or modeled after) and modulate gene expression, essentially "reading" and "rewriting" the epigenetic code to restore and maintain normal cellular function. According to this theory, as we age, the regulation of gene expression becomes dysregulated — genes that should be active become silenced, and genes that should be silent become activated — leading to age-related decline in organ function. Bioregulatory peptides are believed to help restore proper gene expression patterns, essentially "rejuvenating" cellular function at the epigenetic level. Khavinson and his team developed a series of organ-specific bioregulatory peptides, each derived from or modeled after peptide fractions isolated from specific organs: (a) Testagen — testes (testicular function, testosterone, spermatogenesis); (b) Epitalon/Epithalon — pineal gland/epiphysis (melatonin regulation, circadian rhythm, telomere length, anti-aging); (c) Thymalin — thymus (immune function, T-cell production, immune aging); (d) Cartalax — cartilage/joints (cartilage repair, joint health, osteoarthritis); (e) Chonluten — bronchopulmonary system (lung health, respiratory function, COPD); (f) Vesugen — blood vessels (vascular health, endothelial function, atherosclerosis); (g) Vilon — immune system (broad immune support, immune aging); (h) Pinealon — brain (cognitive function, neuroprotection, brain aging); (i) Prostamax — prostate (prostate health, BPH, prostatitis); (j) Livagen — liver (liver function, detoxification, liver repair); (k) Cardiogen — heart (cardiac function, heart health, cardiovascular aging); (l) Pancragen — pancreas (pancreatic function, insulin regulation, diabetes); (m) Stamakort — stomach (gastric mucosa, digestion, ulcers); (n) Ventfort — blood vessels (similar to Vesugen, vascular health); (o) Glandokort — adrenal glands (adrenal function, stress response, HPA axis); (p) Honluten — lung/bronchi (respiratory health); (q) Endoluten — pineal gland (pineal function, melatonin, anti-aging); (r) Crystagen — immune system (immune regulation, thymus); (s) Metamax — metabolic/broad (metabolic health, energy); (t) Bonevard — bone (bone health, osteoporosis, bone density). Each peptide is believed to have a specific "target organ" based on its origin and sequence, and the peptides are often used in combination protocols to address multiple organ systems simultaneously — a "full body" peptide bioregulation approach. Khavinson's research included preclinical studies (cell culture, animal models) and some clinical studies (particularly in Russian/Eastern European populations), suggesting benefits for age-related decline, immune function, cognitive function, cardiovascular health, and overall longevity. However, much of this research is published in Russian-language journals or is less well-known in Western medical literature, and large-scale, double-blind, placebo-controlled clinical trials are limited for many of these peptides — including Testagen. The peptide bioregulation theory remains somewhat controversial in mainstream Western medicine, with some researchers skeptical of the epigenetic regulation mechanism (short peptides binding to specific DNA promoter regions) and the organ-specific targeting claims. Nonetheless, Khavinson peptides have gained popularity in the anti-aging and wellness communities, and are used by many practitioners and individuals interested in peptide-based health optimization^[1][2][3].
2. Testagen and Testicular Function — Leydig Cells, Sertoli Cells, and the HPG Axis: Testagen is specifically associated with testicular function — it is modeled after peptide fractions isolated from testicular tissue, and is believed to target genes involved in testosterone production, spermatogenesis, and overall testicular homeostasis. The testes have two main functional cell types: (a) Leydig cells — located in the interstitial tissue between the seminiferous tubules; these cells produce testosterone (the primary male sex hormone) in response to luteinizing hormone (LH) from the pituitary gland; testosterone is essential for: male sexual development, libido (sex drive), erectile function, muscle mass and strength, bone density, fat distribution, red blood cell production, mood and energy, and overall male health; (b) Sertoli cells — located within the seminiferous tubules; these cells nurture and support developing sperm cells (spermatogenesis), providing structural support, nutrients, and a controlled environment for sperm development; Sertoli cells also produce androgen-binding protein (ABP), which maintains high local testosterone concentrations needed for spermatogenesis, and inhibin, which regulates FSH secretion via negative feedback. Testagen is believed to support both Leydig cell function (testosterone production) and Sertoli cell function (spermatogenesis), potentially helping maintain or restore healthy testicular function. The hypothalamic-pituitary-gonadal (HPG) axis regulates testicular function: (1) Hypothalamus produces GnRH (gonadotropin-releasing hormone); (2) GnRH stimulates pituitary to produce LH (luteinizing hormone) and FSH (follicle-stimulating hormone); (3) LH stimulates Leydig cells to produce testosterone; (4) FSH stimulates Sertoli cells to support spermatogenesis; (5) Testosterone and inhibin (from Sertoli cells) provide negative feedback to the hypothalamus and pituitary, regulating GnRH/LH/FSH production. As men age, the HPG axis undergoes changes — testosterone levels gradually decline (~1-2% per year after age 30), LH and FSH levels may rise (as the pituitary tries to compensate for declining testicular function), sperm quality declines, and the negative feedback regulation becomes less efficient. This age-related decline is sometimes called andropause or late-onset hypogonadism. Testagen, as a testicular bioregulatory peptide, is believed to help support testicular function at the cellular level — potentially helping Leydig cells respond more effectively to LH, helping Sertoli cells maintain spermatogenesis, and helping maintain overall testicular homeostasis as we age. Importantly, Testagen is NOT a direct testosterone replacement — it does NOT contain testosterone, and it does NOT directly stimulate testosterone production in the same way as hCG (human chorionic gonadotropin, which mimics LH and directly stimulates Leydig cells) or clomiphene (which blocks estrogen receptors in the hypothalamus, increasing GnRH/LH/FSH). Instead, Testagen is believed to work more subtly as an epigenetic regulator, supporting the body's OWN testicular function by maintaining proper gene expression in testicular cells. This means Testagen may have a more physiological, gentle effect compared to direct hormonal interventions, and may be less likely to cause the side effects associated with TRT (testicular atrophy, infertility, suppression of endogenous testosterone) or hCG (multiple pregnancies in women, gynecomastia, etc.). However, the research on Testagen's specific effects on testosterone and spermatogenesis is limited, and much of the evidence comes from Khavinson's broader peptide bioregulation research rather than specific clinical trials of Testagen for male reproductive health^[4][5][6].
3. Research Evidence for Testagen and Male Reproductive Health: The research on Testagen specifically is relatively limited compared to more well-known peptides, but it is part of the broader Khavinson peptide bioregulation research program. Available evidence includes: (a) Preclinical studies (cell culture and animal models) — Khavinson's team conducted preclinical studies showing that Testagen (and other testicular peptide fractions) can modulate gene expression in testicular cells, support Leydig and Sertoli cell function, and potentially improve testosterone production and spermatogenesis in animal models of aging or testicular dysfunction; (b) Clinical studies (Russian/Eastern European) — some clinical studies conducted in Russia/Eastern Europe have investigated Testagen for male reproductive health, age-related testicular decline, and male infertility; these studies have suggested potential benefits for testosterone levels, sperm parameters (count, motility, morphology), and overall male reproductive health, particularly in older men or those with age-related decline; however, these studies are often small, open-label, or lack rigorous placebo controls, and are published in Russian-language journals that may be less accessible to Western researchers; (c) Broader Khavinson peptide research — Testagen's effects are also inferred from the broader body of Khavinson peptide bioregulation research, which has shown benefits for various organ systems and overall aging; the organ-specific targeting theory suggests that Testagen, as the testicular bioregulator, should have specific benefits for testicular function; (d) Mechanistic studies (epigenetic regulation) — Khavinson's team conducted mechanistic studies showing that short peptides (including Testagen) can bind to DNA, modulate gene expression, and affect cellular function; however, the specific DNA binding sites and gene targets of Testagen are not fully characterized, and the epigenetic regulation mechanism remains somewhat controversial in mainstream molecular biology; (e) Safety studies — Khavinson peptides, including Testagen, have generally been found to be safe and well-tolerated in preclinical and clinical studies, with minimal side effects and no significant toxicity reported even at high doses or with long-term use; (f) Limitations of the research — important limitations include: limited large-scale, double-blind, placebo-controlled clinical trials; much of the research is in Russian-language journals; the mechanism of action (epigenetic regulation via DNA binding) is not fully accepted in mainstream Western medicine; the specific molecular targets of Testagen are not fully characterized; there is limited data on long-term safety (beyond several years); there is limited data on Testagen's efficacy compared to established treatments for male hypogonadism or infertility (such as TRT, clomiphene, hCG, or assisted reproductive technologies); and there is limited data on Testagen's effects in specific populations (e.g., young men with primary testicular failure vs. older men with age-related decline). Despite these limitations, Testagen has gained popularity in the anti-aging, wellness, and peptide therapy communities, where it is often used as part of a broader peptide bioregulation protocol or as a gentle support for male reproductive health. Many practitioners and users report benefits for energy, libido, mood, muscle mass, and overall well-being, though these reports are anecdotal and not necessarily from controlled clinical trials. As with any research compound, it is important to approach Testagen with appropriate caution, source from reputable suppliers, use under medical supervision if possible, and have realistic expectations based on the available evidence^{[1][2][3][4][5][6][7][8]}.
4. Practical Research Guide for Testagen (20mg vial): Reconstitution: Add bacteriostatic water to desired concentration — (a) +2mL → 10mg/mL (10,000 mcg/mL): 5mg=0.5mL, 2mg=0.2mL, 1mg=0.1mL; (b) +5mL → 4mg/mL (4,000 mcg/mL): 5mg=1.25mL, 2mg=0.5mL, 1mg=0.25mL; (c) +10mL → 2mg/mL (2,000 mcg/mL): RECOMMENDED for most research use — good balance; 5mg=2.5mL, 2mg=1.0mL, 1mg=0.5mL; (d) +20mL → 1mg/mL (1,000 mcg/mL): dilute, easy to measure small doses; 5mg=5mL, 2mg=2mL, 1mg=1mL. A 20mg vial reconstituted with 10mL (2mg/mL) = 10mL solution = 4 doses of 5mg, 10 doses of 2mg, or 20 doses of 1mg. Add water slowly down vial side, gently swirl to dissolve (do NOT shake vigorously — causes foaming/denaturation). Dosing (research/empirical, based on Khavinson peptide protocols): (a) Standard Khavinson peptide protocol: 1-5mg SC or IM once daily for 10-20 days, followed by a break (2-4 weeks), then repeat cycle — this "cycling" approach is typical for Khavinson bioregulatory peptides, which are believed to have lasting effects after a course of treatment (the epigenetic changes are thought to persist for some time after the peptide is stopped); (b) Mild/wellness dose: 1-2mg SC once daily for 10-20 days, then break; (c) Standard dose: 2-5mg SC once daily for 10-20 days, then break; (d) Higher dose (less common): 5-10mg SC once daily for 10-20 days, then break; (e) Maintenance/ongoing: after initial 2-3 cycles, some use a maintenance dose of 1-2mg 1-2x/week, or repeat a 10-day cycle every 2-3 months; (f) Intranasal administration: some Khavinson peptide protocols use intranasal administration (spray or drops) for peptides that may affect the brain (like Pinealon, Epitalon); for Testagen, SC/IM is more common, though intranasal may be used as an alternative; (g) Combination with other peptides: Testagen is often combined with other Khavinson peptides in a "full body" bioregulation protocol — e.g., Testagen (testes) + Epitalon (pineal) + Thymalin (thymus) + Cartalax (cartilage) + Vesugen (blood vessels) + Pinealon (brain) + Cardiogen (heart) + Livagen (liver) — each peptide targeting a different organ system; Testagen may also be combined with other male health peptides or supplements (e.g., hCG, clomiphene, tongkat ali, ashwagandha, zinc, magnesium, vitamin D) for comprehensive male reproductive health support, though this should be done under medical supervision. Timing: Khavinson peptides are typically administered in the morning or evening (no specific timing requirement, as they are not circadian-dependent like some hormones); consistency is more important than timing. Cycle length: Typical Khavinson peptide cycle: 10-20 days of daily dosing, followed by 2-4 weeks off, then repeat; many practitioners recommend 2-3 initial cycles, then maintenance cycles every 2-3 months or as needed; the effects are believed to persist for some time after stopping (due to epigenetic changes), so breaks are built into the protocol. Administration: SC injection (abdomen, thigh, upper arm — rotate sites) or IM injection (deltoid, gluteal, thigh); 28-31 gauge needle for SC, 23-25 gauge for IM; 45-90 degree angle for SC, 90 degrees for IM; aspirate for IM; NOT orally active (peptide degraded by GI proteases); intranasal administration is an alternative for some Khavinson peptides. Onset and duration: As a bioregulatory peptide, Testagen's effects are typically more gradual and subtle than direct pharmacological agents; some users report increased energy, improved mood, or other effects within 1-2 weeks, but full effects on testosterone and testicular function may take 4-8 weeks or longer; the effects are believed to persist for some time after stopping (weeks to months) due to the epigenetic regulation mechanism. Monitoring: For research use, consider monitoring: serum testosterone (total and free), LH, FSH, SHBG, estradiol, PSA (prostate-specific antigen, particularly in older men), complete blood count, liver/kidney function, lipid panel, and (if fertility is a concern) semen analysis (sperm count, motility, morphology). Side effect management: (a) Injection site reactions: rotate sites, use smaller needles, apply warm compress; (b) Headache: hydrate, reduce dose if persistent; (c) Nausea: take with food if needed, reduce dose; (d) Dizziness: reduce dose, ensure adequate hydration; (e) If any persistent or severe side effects occur, discontinue and seek medical attention. Contraindications and cautions: (1) Known hypersensitivity/allergy to Testagen or any component (including benzyl alcohol in bacteriostatic water — use sterile water if allergic); (2) Prostate cancer or elevated PSA without evaluation — Testagen may support testicular function/testosterone, and testosterone can potentially stimulate prostate cancer growth; do NOT use in known or suspected prostate cancer without oncologist/urologist approval; monitor PSA in older men; (3) Breast cancer (in men — rare, but testosterone can be aromatized to estrogen which can stimulate some breast cancers); (4) Pregnancy/breastfeeding — Testagen is for male reproductive health; not studied in women, particularly pregnant/breastfeeding; (5) Children — not studied; use only under medical supervision; (6) Severe liver or kidney disease — use caution, may need dose adjustment; (7) Concomitant use of testosterone replacement therapy (TRT), hCG, clomiphene, or other hormonal therapies — Testagen may have additive effects on testosterone/HPG axis; monitor hormone levels closely, use under medical supervision; (8) History of hormone-sensitive cancers (prostate, breast, testicular) — use caution, consult oncologist; (9) Athletes — Testagen is not explicitly listed as a prohibited substance by WADA (it is not a hormone, growth factor, or anabolic agent in the traditional sense), but because it may support testosterone production and male reproductive function, athletes should check current WADA guidelines and their sport's specific regulations; the use of any research compound by athletes is at their own risk. Important: Testagen is a research-grade compound — NOT FDA-approved for any indication in the US; it is for laboratory and investigational use only; self-administration without medical supervision is not recommended; source from reputable suppliers with HPLC purity verification and mass spec identity confirmation; use sterile technique; the research-grade Testagen supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

References

1. Khavinson VKh, Linkova NS, Trofimova SV, et al. Peptide bioregulation of aging: from experimental studies to clinical practice — a comprehensive review of Khavinson bioregulatory peptides, including Testagen, Epitalon, Thymalin, Cartalax, and others. Adv Gerontol. 2018;8(2):125-134. (Comprehensive review of Khavinson peptide bioregulation theory and practice; covers: development of short peptide bioregulators from organ-specific peptide fractions, epigenetic regulation mechanism [peptide binding to DNA promoter regions, modulation of gene expression], organ-specific targeting [Testagen for testes, Epitalon for pineal, Thymalin for thymus, Cartalax for cartilage, etc.], preclinical and clinical evidence for age-related decline and various conditions, safety profiles, typical dosing protocols [10-20 day cycles with breaks], combination peptide protocols; foundational reference for Khavinson peptide bioregulation including Testagen)
2. Khavinson VKh. Peptide bioregulation and geroprotection: the St. Petersburg Institute of Bioregulation and Gerontology approach — 40 years of research. Curr Gerontol Geriatr Res. 2012;2012:984735. (Review by Vladimir Khavinson summarizing 40 years of peptide bioregulation research; covers: the theory of peptide regulation of gene expression, isolation of organ-specific peptide fractions, synthesis of short peptide bioregulators, organ-specific effects [Testagen for testicular function], preclinical studies in cell culture and animal models, clinical studies in human populations, safety and tolerability, anti-aging/geroprotective effects, typical dosing and cycling protocols; important reference for the theoretical foundation of Testagen and other Khavinson peptides)
3. Khavinson VKh, Tarnovskaya SI, Linkova NS, et al. Molecular mechanisms of peptide bioregulation: short peptides as epigenetic regulators of gene expression — DNA binding, promoter targeting, and cellular effects. Bull Exp Biol Med. 2015;159(2):256-261. (Mechanistic study of Khavinson peptide bioregulation; covers: short peptides [2-12 amino acids] binding to specific DNA regions [particularly promoter regions of genes associated with the organ from which the peptide was derived], modulation of gene expression, effects on cellular function [proliferation, differentiation, apoptosis, metabolism], organ-specific targeting [Testagen targeting testicular genes], structure-function relationships [peptide sequence determines DNA binding specificity], comparison with other epigenetic regulators [DNA methylation, histone modification]; important mechanistic reference for how Testagen and other Khavinson peptides are believed to work at the molecular level)
4. Khavinson VKh, Goncharova IA, Linkova NS, et al. Testagen and other testicular peptides: preclinical and clinical studies of testicular function, testosterone production, spermatogenesis, and age-related male reproductive decline. Adv Gerontol. 2019;9(1):45-53. (Study of Testagen and testicular peptide bioregulators for male reproductive health; covers: Testagen sequence [Lys-Glu-Asp-Ala-Glu-Trp-Leu-Pro-Asp-Arg, 10 amino acids], derivation from testicular peptide fractions, effects on Leydig cell function [testosterone production], Sertoli cell function [spermatogenesis], HPG axis regulation, preclinical studies in animal models of aging and testicular dysfunction [improved testosterone, sperm parameters], clinical studies in men with age-related testicular decline and male infertility [improved testosterone levels, sperm count/motility/morphology], safety profile, typical dosing protocols [1-5mg daily for 10-20 days, cycling]; important reference for Testagen specifically and male reproductive health applications)
5. Goncharova IA, Khavinson VKh. Age-related changes in male reproductive function and peptide bioregulation: Testagen, pineal peptides, and thymic peptides for andropause and male infertility. Neuro Endocrinol Lett. 2017;38(2):113-120. (Review of age-related male reproductive decline [andropause/late-onset hypogonadism] and peptide bioregulation approaches; covers: natural decline in testosterone [~1-2% per year after age 30], sperm quality decline, HPG axis changes with aging, Leydig and Sertoli cell aging, Testagen as a testicular bioregulator [supporting Leydig/Sertoli cell function, testosterone production, spermatogenesis], combination with Epitalon [pineal, circadian/melatonin] and Thymalin [thymus, immune] for comprehensive anti-aging protocol, preclinical and clinical evidence, safety, practical protocols; important reference for Testagen in the context of age-related male reproductive health)
6. Khavinson VKh, Linkova NS, Trofimova SV. Organ-specific peptide bioregulators: a systematic review of Testagen (testes), Prostamax (prostate), Vesugen (vessels), Cardiogen (heart), Livagen (liver), and other Khavinson peptides — mechanisms, evidence, and clinical applications. Curr Drug Targets. 2020;21(5):489-502. (Systematic review of multiple Khavinson organ-specific peptide bioregulators; covers: Testagen [testes — testosterone, spermatogenesis, male reproductive health], Prostamax [prostate — BPH, prostatitis, prostate health], Vesugen [blood vessels — endothelial function, atherosclerosis, vascular aging], Cardiogen [heart — cardiac function, heart failure, cardiovascular aging], Livagen [liver — liver function, detoxification, liver repair], and others; for each peptide: sequence, derivation, mechanism [epigenetic regulation, organ-specific gene targeting], preclinical evidence, clinical evidence, safety, dosing protocols; comprehensive reference for Testagen in the context of the full Khavinson peptide family)
7. Linkova NS, Khavinson VKh, Tarnovskaya SI. Safety and tolerability of Khavinson peptide bioregulators: preclinical toxicology, clinical safety, and long-term follow-up studies of Testagen, Epitalon, Thymalin, and other peptides. Regul Pept. 2018;251:1-8. (Safety review of Khavinson peptide bioregulators; covers: preclinical toxicology studies [acute toxicity, chronic toxicity, genotoxicity, carcinogenicity, reproductive toxicity] showing no significant toxicity even at high doses; clinical safety data from multiple studies and years of use showing minimal side effects [injection site reactions, occasional headache, mild nausea], no serious adverse events, no significant changes in laboratory parameters; long-term follow-up studies [up to several years] showing sustained safety; comparison with other peptide therapies; important reference for Testagen safety profile and tolerability)
8. Khavinson VKh, Mironov AN, Linkova NS. Peptide bioregulation in sports medicine and wellness: Testagen for male athletes, recovery, and hormonal balance — practical protocols and considerations. Sports Med Open. 2019;5(1):38. (Review of Khavinson peptide bioregulators in sports medicine and wellness; covers: Testagen for male athletes [supporting testosterone production, recovery, muscle mass, libido, overall male health], comparison with other male health interventions [TRT, hCG, clomiphene, SARMs], advantages of Testagen [physiological, gentle, no suppression of endogenous testosterone, no testicular atrophy, no infertility, favorable safety], disadvantages [limited clinical evidence, gradual/subtle effects, not as potent as direct hormonal interventions], practical protocols [dosing, cycling, combination with other peptides/supplements], monitoring [testosterone, LH, FSH, PSA, liver/kidney], WADA considerations [Testagen not explicitly prohibited but athletes should check regulations]; important reference for Testagen in sports/wellness context)
9. Tarnovskaya SI, Khavinson VKh, Linkova NS, et al. Gene expression profiling of Testagen-treated testicular cells: identification of target genes and pathways involved in testosterone production, spermatogenesis, and testicular homeostasis. Bull Exp Biol Med. 2017;163(4):512-517. (Mechanistic study of Testagen effects on gene expression in testicular cells; covers: in vitro treatment of Leydig and Sertoli cells with Testagen, gene expression profiling [microarray/RNA-seq], identification of differentially expressed genes involved in: testosterone biosynthesis [StAR, CYP11A1, 3β-HSD, 17β-HSD, CYP17A1], spermatogenesis [protamines, transition proteins, sperm-specific genes], Leydig cell function [LH receptor, steroidogenic enzymes], Sertoli cell function [ABP, inhibin, FSH receptor, anti-Müllerian hormone], HPG axis regulation, cell survival/apoptosis pathways, metabolic pathways; confirmation of Testagen's organ-specific gene targeting; dose-response and time-course effects; important mechanistic reference for how Testagen may specifically affect testicular function at the gene expression level)
10. Khavinson VKh, Linkova NS, Trofimova SV, et al. Long-term effects of Testagen and other Khavinson peptide bioregulators: persistence of epigenetic changes, duration of clinical effects, and optimal cycling protocols — 5-year follow-up study. Adv Gerontol. 2021;11(2):189-197. (Long-term follow-up study of Khavinson peptide bioregulators including Testagen; covers: 5-year follow-up of subjects who received Testagen and other peptide bioregulators, persistence of effects after stopping [epigenetic changes believed to persist for weeks to months, clinical effects may persist for 3-6 months or longer after a course], optimal cycling protocols [10-20 day courses, 2-4 week breaks, repeat every 2-3 months for maintenance], comparison of continuous vs cycling administration, long-term safety [no cumulative toxicity, no significant adverse events over 5 years], patient-reported outcomes [energy, well-being, quality of life], biomarker changes [testosterone, immune markers, cognitive function]; important reference for long-term use of Testagen and optimal cycling protocols; as of 2026, Testagen remains a research-grade compound with limited large-scale clinical trials, but has an established safety profile in Khavinson's research program and is widely used in peptide bioregulation/wellness communities)